Drug Discovery Market

Drug Discovery Market - Business Segmentation by
Revenue, Market Landscape, Present Scenario and Growth
Prospects 2026
Advancements in the field of biotechnology and pharmaceuticals, in order to identify active
ingredients in the form of drugs through drug discovery process, is gradually gaining pace in
the market. This drug discovery process involves screening of chemical libraries, identification
of the active ingredients for a natural remedy or by serendipitous discovery. Emergence of new
diseases, which include viral or infectious diseases leads to high demand for drug discovery for
these conditions. However, development of drugs is complex, costly, and risky process.
Download PDF Brochure Of This Research Report @
The objective of drug discovery is to recognize the investigational drug success rates by stages,
pre-clinical studies, investigational new drug application-Phase I, Phase II, Phase III studies,
new drug application, and phase IV studies. The success during drug discovery process is very
low, as according to data published by Journal Research & Review 2016. According to the data,
it was estimated that among 5,000-10,000 drug discovery screening, only 250 enter the
preclinical testing and 5 enter the clinical testing and only 1 drug is approved by the regulatory
body, which takes roughly 5-10 years.
Furthermore, according to the same source, drug discovery process takes around 5-10 years for
the complete drug discovery, development, and introduction in the market, which costs around
US$1.7 Bn for complete process to undergo successfully.
Drug Discovery Market Dynamics:
A patent cliff provides an opportunity for manufactures to collaborate and participate in current
drug discovery model to sustain in the market. Manufacturers such as, Eli Lilly, Pfizer, Takeda,
Bristol-Myers Squibb and Gilead lost their patent in 2017, with some of their respective big
sellers that cover a range of indications such as multiple sclerosis, HIV, erectile dysfunction,
and cancer. Such patent loss forces companies to introduce innovative products to retain their
revenues and increase their revenue. After patent expiration, generic manufacturers enter the
market and provide drugs that are equivalent to the innovator’s drugs, however, at a
significantly lower price. Therefore, manufacturers are focusing on developing new and
innovative products to sustain in the competitive market.
Increasing prevalence of wide range of disease such as cancer, cardiovascular, and CNS-related
disorders with patent expiration of blockbuster drugs are some of the driving factors for growth
of the drug discovery market. According to the World Cancer Research Fund International,
2015, an estimated 124,000 new cases of myeloma were diagnosed globally in 2015, which
accounted for 0.8% of the total cancer cases. The mortality rate of the disease is around 0.9%
of all cancer deaths, accounting for 87,000 deaths each year. Therefore, key manufacturers are
actively involved in the development of immunotherapies targeting B-cell maturation antigen
(BCMA) such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, and
antibody drug conjugates (ADCs). For instance, in 2012, the University of Pennsylvania and
Novartis entered into an exclusive global research and licensing agreement to study and
commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR)
technologies. In 2016, Juno Therapeutics entered into a licensing agreement with Memorial
Sloan Kettering Cancer Center (MSKCC) and Eureka Therapeutics for developing CAR T cell
immunotherapy against multiple novel targets.
Drug Discovery Market - Regional Insights:
North America accounted for the largest share in the drug discovery market, followed by
Europe market in 2016. This is attributed to presence of a large number of top pharmaceutical
and biotech companies, Pfizer, Inc., Merck, GlaxoSmithKline, Novartis and many more in this
region. Furthermore, favorable regulatory framework and regulatory policies for investors for
research and development of new drugs augments growth of drug discovery market in the
region. The US Regulatory Framework provides for 3 distinct regulatory approval pathways
outlined in the Food, Drug, and Cosmetics Act (FD&C Act), which allows the registration of
novel compounds, new drugs containing similar ingredients to previously approved products and
generic copies of previously approved products in systematic way helping the pharmaceutical
companies to gain approval over the new drugs.
Report includes chapters
• Drug Discovery Market
• Drug Discovery Market
Opportunity Map (COM)
• Drug Discovery Market
which deeply display the following deliverable about industry :
Research Objective and Assumption
Purview - Report Description, Executive Summary, and Coherent
Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Drug Discovery Market, By Regions
• Drug Discovery Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Drug Discovery Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Drug Discovery Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Drug Discovery Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Browse Complete Report For More Information @
Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding
in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides
better access to patients for clinical trials, with lower cost operational efficiencies. Increasing
government investment in research and development is also expected to foster growth of drug
discovery in Asia Pacific region. For instance, in March 2011, the Korean government
participated in the Korean National Enterprise for Clinical Trials, to advance the country’s
infrastructure for conducting clinical trials, which could fasten the process of clinical trials, in
turn supporting the growth of drug discovery market.
Drug Discovery Market - Competitive Analysis:
Pfizer Inc.
GlaxoSmithKline LLC
Merck & Co. Inc.
Agilent Technologies Inc.
Eli Lilly and Company
F Hoffmann-La Roche Ltd
Bayer AG
Abbott Laboratories Inc.
AstraZeneca PLC
Shimadzu Corp.
Drug Discovery Market Taxonomy:
By Drug Type:
• Small Molecule Drug
• Biologics Drug
By Technology:
• High Throughput Screening
• Biochips
• Bioinformatics
• Pharmacogenomics and Pharmacogenetics
• Combinatorial Chemistry
• Nanotechnology
• Spectroscopy
• Metabolomics
• Other Technologies
By Services:
• Drug Metabolism and Pharmacokinetics (DMPK) Services
• Pharmaceutical Services
• Chemical Services
• Biological Services
By End User
• Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Other End Users
By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
Inquire Here Before Purchase Of This Research Report @
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

The objective of drug discovery is to recognize the investigational drug success rates by stages, pre-clinical studies, investigational new drug application-Phase I, Phase II, Phase III studies